KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Retained Earnings (2020 - 2025)

Ginkgo Bioworks Holdings' Retained Earnings history spans 6 years, with the latest figure at -$6.2 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 5.36% year-over-year to -$6.2 billion; the TTM value through Dec 2025 reached -$6.2 billion, down 5.36%, while the annual FY2025 figure was -$6.2 billion, 5.36% down from the prior year.
  • Retained Earnings reached -$6.2 billion in Q4 2025 per DNA's latest filing, down from -$6.1 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $5.2 million in Q1 2022 to a low of -$6.2 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$2.4 billion, with a median of -$51.4 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: surged 100.03% in 2023, then crashed 2307920.91% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$1.7 million in 2021, then plummeted by 256323.27% to -$4.4 billion in 2022, then surged by 100.03% to $1.5 million in 2023, then tumbled by 393466.37% to -$5.8 billion in 2024, then decreased by 5.36% to -$6.2 billion in 2025.
  • Per Business Quant, the three most recent readings for DNA's Retained Earnings are -$6.2 billion (Q4 2025), -$6.1 billion (Q3 2025), and -$6.0 billion (Q2 2025).